天津医药 ›› 2023, Vol. 51 ›› Issue (5): 522-526.doi: 10.11958/20221409

• 临床研究 • 上一篇    下一篇

GPR120和GPR40表达与卵巢癌临床病理特征及预后的关系

李娟(), 倪惠华()   

  1. 南通大学附属医院妇产科(邮编226000)
  • 收稿日期:2022-09-05 修回日期:2022-11-24 出版日期:2023-05-15 发布日期:2023-05-05
  • 通讯作者: △E-mail:yyy123hs@163.com
  • 作者简介:李娟(1980),女,主治医师,主要从事妇科肿瘤的诊断和治疗方面研究。E-mail:lijuan1980nt@163.com
  • 基金资助:
    2019年度南通市市级科技计划(指导性)项目(MSZ19102)

Relationship between the expression of GPR120 and GPR40 and clinicopathological features and survival outcome of ovarian cancer patients

LI Juan(), NI Huihua()   

  1. Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong 226000, China
  • Received:2022-09-05 Revised:2022-11-24 Published:2023-05-15 Online:2023-05-05
  • Contact: △E-mail:yyy123hs@163.com

摘要:

目的 探讨G蛋白偶联受体(GPR)120与GPR40在卵巢癌中的表达及其作为预后分子标志物的临床价值。方法 通过免疫组织化学染色检测128例卵巢癌患者的石蜡包埋样本中GPR120与GPR40表达。分析GPR120、GPR40表达与卵巢癌临床病理特征之间的关系,采用Kaplan-Meier法绘制高表达和低表达GPR120、GPR40患者的生存曲线,Cox风险回归模型分析卵巢癌患者无病生存(DFS)率的影响因素。结果 卵巢癌患者GPR120与GPR40阳性表达率分别为62.5%(80/128)和56.3%(72/128)。FIGOⅡ—Ⅲ期和组织学G3级患者的GPR120和GPR40高表达率分别高于FIGOⅠ期与组织学G1—G2级。生存分析表明,GPR120高表达者的4年DFS较低表达者下降(56.9% vs. 70.7%,Log-rank χ2=5.144,P=0.023)。此外,GPR40高表达者的DFS率亦低于低表达组(57.7% vs. 68.4%,Log-rank χ2=4.491,P=0.034)。单、多变量Cox回归分析认定GPR120高表达、GPR40高表达、FIGO分期Ⅱ—Ⅲ期和术后残留灶≥1 cm是卵巢癌患者DFS的独立影响因素。结论 GPR120与GPR40是预测卵巢癌侵袭性与不良预后的有效分子标志物,两者可能参与了卵巢癌的恶性转化与进展。

关键词: 卵巢肿瘤, G蛋白偶联受体120, G蛋白偶联受体40, 预后, 无病生存, 分子标志物

Abstract:

Objective To investigate the expression of G protein coupled receptor 120 (GPR120) and G protein coupled receptor 40 (GPR40) and their clinical value as prognostic biomarkers for ovarian cancer patients. Methods The paraffin embedded samples and clinicopathological data of 128 ovarian cancer patients were systematically collected. The expression levels of GPR120 and GPR40 in ovarian cancer samples were detected by immunohistochemistry, and the relationships between expression levels of GPR120 and GPR40 and clinicopathological characteristics of ovarian cancer patients were analyzed. Kaplan-Meier method was used to draw survival curves of patients with high and low expression levels of GPR120 and GPR40, and Cox proportional hazard model were used to analyze predictors of disease free survival (DFS) for ovarian cancer patients. Results The positive rates of GPR120 and GPR40 expression in ovarian cancer samples were 62.5% (80/128) and 56.3% (72/128), respectively. The positive expression rates of GPR120 in patients with FIGO stage Ⅱ—Ⅲ and histology G3 were significantly higher than those in patients with FIGO stage Ⅰ and histology G1—G2, respectively. Similarly, the positive expression rates of GPR40 in FIGO Ⅱ—Ⅲ and histologic G3 patients were significantly higher than those in patients with FIGO Ⅰ and histologic G1—G2, respectively. Survival analysis showed that the 4-year DFS rate of patients with high GPR120 expression was decreased compared with that of patients with low GPR120 expression (56.9% vs. 70.7%, Log-rank χ2= 5.144, P=0.023). The 4-year DFS rate of patients with high GPR40 expression was significantly lower than that of patients with low GPR40 expression (57.7% vs. 68.4%,Log-rank χ2= 4.491, P=0.034). The univariate and multivariate Cox regression analysis identified that high GPR120 expression, high GPR40 expression, FIGO stage Ⅱ—Ⅲ and residual disease size ≥ 1 cm were independent prognostic factors for ovarian cancer patients. Conclusion GPR120 and GPR40 are useful biomarkers to predict aggressive features and poor prognosis of ovarian cancer patients, and their dysregulation might be implicated in malignant transformation and cancer progression.

Key words: ovarian neoplasms, G protein coupled receptor 120, G protein coupled receptor 40, prognosis, disease-free survival, biomarkers

中图分类号: